ÖZET
Amaç:
Bu çalışmada fibromiyalji sendromlu (FMS) kadın hastalarda nöropatik ağrının değerlendirilmesi ve obezitenin fibromiyalji semptomları, yaşam kalitesi ve nöropatik ağrı üzerine etkisinin değerlendirilmesi amaçlandı.
Gereç ve Yöntem:
Bu çalışma fibromiyalji teşhisi konulan 40 normal kilolu ve 40 obez hastayı içermiştir. Çalışmaya dahil edilen hastalar Amerikan Romatoloji Koleji (American College of Rheumatology) 1990 ve 2010 sınıflama kriterlerinin tümünü karşılamışlardır. Hastaların nöropatik ağrı düzeyini değerlendirmek için Leeds Nöropatik Semptom ve Bulgu Değerlendirme (LANSS) ve Douleur Nöropatik 4 sorgulama (DN4) ölçekleri kullanıldı. Hastaların yaşam kalitesini değerlendirmek için Fibromiyalji Etki Anketi (FIQ) ölçeği kullanıldı.
Bulgular:
Nöropatik ağrı LANSS skalasına göre %56,3, DN4 skalasına göre %78 hastada saptandı. Nöropatik ağrı oranı normal kilolu FMS’li grupta %42,5, obez FMS’li grupta %70 oranındaydı ve obez grupta istatistiksel olarak anlamlı olarak daha yüksekti. FIQ skorları iki grup arasında anlamlı farklı saptanmadı.
Sonuç:
Nöropatik ağrı obez kadın FMS hastalarında normal kilolu kadın FMS hastalarına göre anlamlı daha yüksek çıkmıştır, bu nedenle FMS’li kadın hastalarda obez olanlarda nöropatik ağrı açısından daha dikkatli olunmalıdır.
References
1
Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord 2007;8:27.
2
Kılıç E, Özgöçmen S. Fibromyalgia and Neuropathic Pain. Turk Klin Physic Med and Rehab 2012;5:11-18.
3
Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 2010;9:807-19.
4
Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 2007;26:465-73.
5
Maletic V, Raison CL. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci (Landmark Ed) 2009;14:5291-338.
6
Cheng CW, Wong CS, Hui GK, Chung EK, Wong SH. Fibromyalgia: is it a neuropathic pain? Pain Manag 2018;8:377-88.
7
Okifuji A, Bradshaw DH, Olson C. Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. Clin Rheumatol 2009;28:475-8.
8
Ursini F, Naty S, Grembiale RD. Fibromyalgia and obesity: the hidden link. Rheumatol Int 2011;31:1403-8.
9
Vuolteenaho K, Koskinen A, Moilanen E. Leptin - a link between obesity and osteoarthritis. applications for prevention and treatment. Basic Clin Pharmacol Toxicol 2014;114:103-8.
10
Hozumi J, Sumitani M, Matsubayashi Y, Abe H, Oshima Y, Chikuda H, et al. Relationship between Neuropathic Pain and Obesity. Pain Res Manag 2016;2016:2487924.
11
Blokh Kerpel A, Tiosano S, Amital D, Comaneshter D, Cohen AD, Amital H. [ASSOCIATION OF OBESITY, SMOKING AND SOCIOECONOMIC STRATA WITH THE FIBROMYALGIA SYNDROME]. Harefuah 2019;158:583-6.
12
Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72.
13
Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010;62:600-10.
14
WHO Expert Committee. Physical Status: the use and interpretation of anthropometry. WHO Technical Report Series no. 854. Geneva: WHO, 1995. https://apps.who.int/iris/handle/10665/37003
15
Fredy M. The graphic rating scale. Journal of educational psychology 1923;14:83-102.
16
Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001;92:147-57.
17
Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 2005;114:29-36.
18
Unal-Cevik I, Sarioglu-Ay S, Evcik D. A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4. J Pain 2010;11:1129-35.
19
Yucel A, Senocak M, Kocasoy Orhan E, Cimen A, Ertas M. Results of the Leeds assessment of neuropathic symptoms and signs pain scale in Turkey: a validation study. J Pain 2004;5:427-32.
20
Burckhardt CS, Clark SR, Bennett RM. The fibromyalgia impact questionnaire: development and validation. J Rheumatol 1991;18:728-33.
21
Sarmer S, Ergin S, Yavuzer G. The validity and reliability of the Turkish version of the Fibromyalgia Impact Questionnaire. Rheumatol Int 2000;20:9-12.
22
Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911-20.
23
Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-99.
24
Martínez-Lavin M, López S, Medina M, Nava A. Use of the leeds assessment of neuropathic symptoms and signs questionnaire in patients with fibromyalgia. Semin Arthritis Rheum 2003;32:407-11.
25
Giske L, Bautz-Holter E, Sandvik L, Røe C. Relationship between pain and neuropathic symptoms in chronic musculoskeletal pain. Pain Med 2009;10:910-7.
26
Pamuk ON, Yeşil Y, Cakir N. Factors that affect the number of tender points in fibromyalgia and chronic widespread pain patients who did not meet the ACR 1990 criteria for fibromyalgia: are tender points a reflection of neuropathic pain? Semin Arthritis Rheum 2006;36:130-4.
27
Gauffin J, Hankama T, Kautiainen H, Hannonen P, Haanpää M. Neuropathic pain and use of PainDETECT in patients with fibromyalgia: a cohort study. BMC Neurol 2013;13:21.
28
Marques AP, Ferreira EA, Matsutani LA, Pereira CA, Assumpção A. Quantifying pain threshold and quality of life of fibromyalgia patients. Clin Rheumatol 2005;24:266-71.
29
Çiğdem B, Yesim SA, Yesim K. Primer fibromiyalji sendromlu hastalarda yasam kalitesi: Ege Fiz Tıp Reh Der 1999;5:241-5.
30
Tüzün EH, Albayrak G, Eker L, Sözay S, Daşkapan A. A comparison study of quality of life in women with fibromyalgia and myofascial pain syndrome. Disabil Rehabil 2004;26:198-202.
31
Rombaut L, Malfait F, De Paepe A, Rimbaut S, Verbruggen G, De Wandele I, et al. Impairment and impact of pain in female patients with Ehlers-Danlos syndrome: a comparative study with fibromyalgia and rheumatoid arthritis. Arthritis Rheum 2011;63:1979-87.
32
Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000;27:2683-91.
33
Gota CE, Kaouk S, Wilke WS. Fibromyalgia and Obesity: The Association Between Body Mass Index and Disability, Depression, History of Abuse, Medications, and Comorbidities. J Clin Rheumatol 2015;21:289-95.
34
Bjersing JL, Erlandsson M, Bokarewa MI, Mannerkorpi K. Exercise and obesity in fibromyalgia: beneficial roles of IGF-1 and resistin? Arthritis Res Ther 2013;15:R34.
35
McKendall MJ, Haier RJ. Pain sensitivity and obesity. Psychiatry Res 1983;8:119-25.
36
Zhang Y, Zhang S, Gao Y, Tan A, Yang X, Zhang H, et al. Factors associated with the pressure pain threshold in healthy Chinese men. Pain Med 2013;14:1291-300.
